首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 78 毫秒
1.
川崎病患儿白细胞介素-15水平变化的临床意义   总被引:1,自引:0,他引:1  
目的探讨白细胞介素-15(IL-15)在川崎病(KD)发病机制中的作用及其应用价值。方法选择2004年10月~2006年1月本院住院的30例KD患儿作为研究对象,采用酶联免疫吸附法(ELISA)检测KD患儿急性期和恢复期血清IL-15水平,同期检测30例下呼吸道感染发热期和20例正常健康儿童作为对照。结果急性期KD患儿血清IL-15水平明显高于健康对照组,二者比较有显著性差异(q=25.64P〈0.01);恢复期KD患儿血清IL-15水平下降,但仍较健康对照组增高,二者比较有显著性差异(q=4.00P〈0.01);KD患儿血清IL-15水平急性期与恢复期比较有显著性差异(t=14.87P〈0.01)。KD患儿急性期和恢复期血清IL-15水平均明显高于下呼吸道感染患儿急性期和恢复期,有显著性差异(急性期t=6.28P〈0.01;恢复期t=4.34P〈0.01);急性期随KD患儿IL-15水平升高,ESR也相应升高,二者呈显著正相关(r=0.371P=0.044),但与外周血WBC计数、CRP和血清清蛋白(ALB)变化无明显相关性;与IgG存在正相关性(r=0.372P=0.043)。结论IL-15参与KD的病理生理过程,IL-15可能促使免疫细胞大量激活,进而介导组织免疫病理损伤。IL-15水平变化反映KD的病情状况,可能为早期诊断提供一定线索。  相似文献   

2.
目的:为正确认识肺炎支原体肺炎(MPP)患儿免疫状态,该研究检测了MPP和非肺炎支原体肺炎患儿血清白细胞介素6(IL6)及可溶性白细胞介素6受体(sIL6R)的变化,探讨其对MPP和非MPP患儿病情的影响,并为选择合理的MPP治疗手段提供理论依据。方法:用ELISA法检测MPP患儿(n=41)及非MPP患儿(n=20)急性期和恢复期血清IL-6及sIL-6R含量。结果:①MPP 患儿血清IL-6急性期和恢复期分别为 2.01±0.41,1.12±0.67 ng/L;sIL-6R急性期和恢复期分别为 1.87±0.25,1.92±0.27 μg/L,均明显高于正常对照组 0.37±0.52 ng/L,1.71±0.15 μg/L,差异有显著性(P<0.01);MPP患儿恢复期血清IL-6含量较急性期明显下降,差异有显著性(P<0.01),而sIL-6R恢复期与急性期比较差异无显著性(P>0.05);②非MPP患儿血清IL-6急性期及恢复期分别为1.56±0.26,0.84±0.63 ng/L,明显高于正常对照组,差异有显著性(P<0.01或P<0.05),而血清sIL-6R与对照组比较差异无显著性(P>0.05);非MPP患儿急性期血清IL-6高于恢复期,差异有显著性(P<0.05),血清sIL-6R急性期与恢复期比较差异无显著性(P>0.05);③MPP患儿急性期血清IL-6、sIL-6R含量较非MPP患儿急性期升高(P<0.01或P<0.05);MPP患儿恢复期血清IL-6含量与非MPP患儿恢复期的差异无显著性(P>0.05);MPP患儿恢复期血清sIL-6R含量明显高于非MPP患儿恢复期(P<0.01)。结论:MPP患儿血清IL-6及sIL-6R改变较非MPP患儿明显,提示MPP患儿免疫功能改变较非MPP患儿显著,IL-6及sIL-6R参与了MPP的发生和发展,有必要对MPP患儿进行免疫调节治疗。  相似文献   

3.
目的探讨肺炎支原体肺炎(mycoplasma pneumoniae pneumonia, MPP)患儿血清中神经生长因子(nerve growth factor,NGF)、白细胞介素(interleukin,IL)-15的水平变化及其临床意义。方法采用酶联免疫吸附法对65例MPP患儿(重症组25例,轻症组40例)和50例健康儿童(对照组)的血清NGF和IL-15水平进行测定。结果检测血清NGF、IL-15水平,MPP组急性期分别为(157.62±33.45)pg/ml和(242.51±60.04)pg/ml,恢复期分别为(99.58±21.29)pg/ml和(145.90±50.25)pg/ml,均较对照组明显升高[(29.86±11.74)pg/ml,(108.86±21.14)pg/ml],且急性期NGF、IL-15水平显著高于恢复期,差异有统计学意义(P〈0.05)。在MPP急性期,重症组血清NGF、IL-15水平显著高于轻症组[(204.38±27.52)pg/mlvs(128.39±22.07)pg/ml,(288.58±55.33)pg/mlvs(213.71±42.69)pg/ml],差异有统计学意义(P〈0.05);在MPP恢复期,重症组血清NGF、IL-15水平高于轻症组,差异无统计学意义(P〉0.05)。结论肺炎支原体感染后,患儿血清中NGF、IL-15水平明显升高,随着病情的缓解而降低,提示NGF、IL-15参与肺炎支原体感染的发病过程。  相似文献   

4.
目的 探讨肺炎支原体 (MP)肺炎患儿血清白细胞介素 10 (IL 10 )、可溶性白细胞介素 2受体 (sIL 2R)水平测定的临床意义。方法 测定MP肺炎患儿 2 6例、普通肺炎 18例急性期及恢复期IL 10、sIL 2R水平 ,并与正常对照组比较。结果 急性期MP肺炎组IL 10较正常对照组明显下降 ,有显著性差异 (P <0 .0 1) ;普通肺炎组与正常对照组无差异 (P >0 .0 5) ;恢复期两组与对照组比较无差异。急性期MP组和普通肺炎组患儿sIL 2R明显增高 ,与对照组比较有显著性差异 (P均 <0 .0 5) ;恢复期MP组患儿sIL 2R下降不明显 ,普通肺炎组患儿明显下降 (P >0 .0 5)。结论 sIL 2R增高显示细胞免疫功能受抑 ,IL 10在MP肺炎患儿低水平 ,显示机体免疫失衡 ,与疾病恢复慢、住院时间长有关  相似文献   

5.
目的探讨肺炎支原体肺炎(MPP)患儿急性期及恢复期外周血IL-10、转化生长因子-β1(TGFβ-1)水平变化的临床意义。方法采用双抗体夹心酶联免疫吸附法(ELISA)测定26例MPP急性期和其中恢复期9例患儿及12例健康儿童血清IL-10、TGFβ-1水平。比较MPP急性期与恢复期IL-10、TGFβ-1的差异。结果MPP急性期及恢复期患儿血清IL-10水平均显著低于对照组(P〈0.01,0.05),急性期及恢复期MPP患儿血清TGFβ-1均明显高于对照组(Pa〈0.01)。MPP患儿急性期与恢复期IL-10、TGFβ-1无明显差异(Pa〉0.05)。结论IL-10低水平表达与MPP发病可能有关,存在炎症反应失控,同时存在以TGFβ-1高水平表达的抗感染反应占优势。  相似文献   

6.
目的探讨白细胞介素(interleukin,IL)-12在毛细支气管炎发病过程中的意义。方法选取59例2岁以下毛细支气管炎患儿,分为毛支Ⅰ组(n=28)和毛支Ⅱ组(n=31),其中毛支Ⅰ组为具有特应质高危因素的患儿,毛支Ⅱ组为无特应质高危因素的患儿。同期住院的同年龄段支气管肺炎患儿36例和患有疝气、肾结石等非感染性疾病术前患儿31例分别作为肺炎对照组和正常对照组,分别检测4组患儿外周血IL-12的水平。结果毛支Ⅰ组患儿外周血IL-12为(34.72±7.96)pg/ml;毛支Ⅱ组患儿外周血IL-12为(55.30±6.72)pg/ml;肺炎对照组患儿及正常对照组患儿外周血IL-12分别为(56.79±10.36)pg/ml、(61.23±11.51)pg/ml,其中毛支Ⅰ组与毛支Ⅱ组相比,外周血IL-12水平降低,差异有统计学意义(P〈0.05);毛支Ⅰ组与肺炎对照组、正常对照组相比,外周血IL-12水平显著降低,差异有统计学意义(P〈0.05);毛支Ⅱ组与肺炎对照组、正常对照组相比,外周血IL-12水平降低,差异有统计学意义(P〈0.05);肺炎对照组与正常对照组相比,外周血IL-12水平差异无统计学意义(P〉0.05)。结论血清IL-12降低是毛细支气管炎发病的重要因素,具有特应质高危因素的毛细支气管炎患儿IL-12降低更为明显。  相似文献   

7.
肺炎患儿血清一氧化氮和白细胞介素—8测定的临床意义   总被引:3,自引:2,他引:1  
目的 探讨肺炎患儿血清NO代谢产物(NO2^-/NO3^-)和白细胞介素-8(IL-8)测定的临床意义。方法 采用硝酸酶还原法和ELISA法分别测定40例肺炎患儿急性期和恢复期血清NO2^-/NO3^-和IL-8水平,23例健康儿童为对照组。结果 治疗前肺炎组NO2^-/NO3^-和IL-8水平较对照组显著增高(P<0.05);治疗后无显著性差异;肺炎组治疗前后比较NO2^-/NO3^-和IL-8水平显著增高(P<0.05)。结论 NO和IL-8参与了支气管肺炎的发生和发展过程。  相似文献   

8.
目的探讨早产儿血清白细胞介素1β(IL-1β)和白细胞介素6(IL-6)水平变化及其与脑血流的关系。方法选择2010年10月至2011年10月我院新生儿重症监护病房收治、胎龄28~33周的单胎早产儿100例,根据是否发生脑室周围-脑室内出血(PIVH)分为观察组和对照组,并根据出血严重程度将观察组分为轻度组和重度组,全部研究对象均在生后第3天、第10天采血应用双夹心酶联免疫吸附法测定血清IL-1β和IL-6的浓度,同期进行头颅彩超检测收缩期血流速度与舒张末期血流速度比值(S/D值)和阻力指数(RI)。结果纳入的100例早产儿中77例发生PIVH,其中轻度组65例,重度组12例,未发生PIVH对照组23例。胎龄28~31周早产儿PIVH发生率与32~33周早产儿差异无统计学意义(P〉0.05),但重度PIVH比例高于32~33周早产儿(27.6%比8.3%,P〈0.05)。出生体重≤1500 g和1501~2000 g早产儿PIVH发生率高于〉2000 g早产儿(90.0%、88.5%比46.4%,P〈0.05),重度PIVH比例高于〉2000 g早产儿(33.3%、4.3%比15.4%,P〈0.05)。生后第3天重度组患儿血清IL-1β(μg/L)、IL-6(μg/L)及头颅彩超S/D值、RI水平高于轻度组和对照组[IL-1β:(90.1±7.4)比(42.7±4.0)、(16.5±4.7),IL-6:(102.5±8.2)比(55.3±7.2)、(20.2±4.4),S/D:(6.65±1.32)比(4.12±0.11)、(2.89±0.13),RI:(0.85±0.12)比(0.72±0.08)、(0.66±0.05),P〈0.05];第10天,轻度组患儿血清IL-1β、IL-6及头颅彩超S/D值、RI水平已恢复至对照组水平(P〉0.05),重度组患儿仍高于轻度组及对照组(P〈0.05);轻度组及重度组生后第10天血清IL-1β、IL-6及头颅彩超S/D值、RI水平与第3天相比均明显降低(P〈0.05)。PIVH患儿血清IL-1β、IL-6水平与S/D值、RI水平均呈正相关(r〉0.5,P均〈0.05)。结论血清IL-1β、IL-6水平与颅内出血病情及脑血流有关,动态监测血清IL-1β、IL-6水平有利于判断?  相似文献   

9.
目的探讨哮喘患儿急性发作期血清IL-25、12水平变化及其在哮喘发病中的作用。方法随机选取于本院就诊的哮喘急性发作期患儿30例作为观察组。男20例,女10例;年龄4~13岁;发作程度:轻度8例,中度17例,重度5例。随机选取同期同年龄组健康体检儿童27例作为健康对照组。男18例,女9例;年龄4~14岁。二组年龄及性别均无统计学差异(Pa〉0.05)。分别抽取各组儿童静脉血4mL,离心后留取血清标本置-70℃冰箱保存,采用ELISA法测定二组儿童血清IL-25、12水平。结果哮喘急性发作期患儿血清IL-25水平[(56.75&#177;11.68)ng/L]显著高于健康对照组[(45.77&#177;10.43)ng/L],差异有统计学意义(t=3.726P〈0.05);哮喘急性发作期患儿血清IL-12水平[(42.12&#177;12.96)ng/L]显著低于健康对照组[(57.12&#177;14.42)ng/L],差异有统计学意义(t=-4.136P〈0.05);血清IL-25水平与IL-12水平呈显著负相关(r=-0.420P〈0.01)。结论哮喘患儿急性发作期血清IL-25水平升高和IL-12水平降低与哮喘的发作关系密切。增强IL-2的活性,可为哮喘的治疗提供新的靶点与理论依据。  相似文献   

10.
目的探讨不同时期HIE新生儿血清脂联素与IL-6水平和其相关性,及其与HIE临床分度的关系。方法采用ELISA法对58例HIE患儿(HIE组)及26例非HIE新生儿(对照组)血清脂联素与IL-6水平进行动态检测,并对检测结果采用SPSS 10.0软件进行统计学处理。结果中、重度HIE组急性期血清脂联素水平与轻度组及对照组比较均明湿下降(Pa〈0.001),重度组较中度组明显下降(P〈0.001);恢复期,中、重度组血清脂联素水平仍明显低于轻度HIE及对照组(Pa〈0.001),重度组明显低于中度组(P〈0.01);急性期,中、重度HIE患儿血清脂联素水平降低,与恢复期比较均有差异性显著(Pa〈0.001),轻度HIE组和对照组血清脂联素水平在急性期和恢复期比较差异均无统计学意义(Pa〉0.05)。中、重度组HIE患儿急性期血清IL-6水平与对照组及轻度组比较均明显升高(Pa〈0.001),重度组与中度组比较亦明显升高(P〈0.001);恢复期,中、重度组血清IL-6水平仍明显高于轻度HIE及对照组(Pa〈0.001),重度组明显高于中度组(P〈0.001);急性期,中、重度HIE患儿血清IL-6水平升高,均明显高于恢复期(Pa〈0.001),轻度HIE组和对照组患儿血清IL-6水平在急性期和恢复期比较差异均无统计学意义(Pa〉0.05)。HIE患儿血清脂联素与IL-6水平呈显著负相关(r=-0.852 P〈0.001)。结论检测血清脂联素和IL-6水平可作为临床HIE病情程度的判断指标之一,对临床诊断及预后的判断具有指导意义。  相似文献   

11.
12.
目的 病毒性心肌炎 (VM)目前尚无有效的治疗方法 ,探讨白细胞介素 6 (IL 6 )、可溶性白细胞介素 6受体 (SIL 6R)与病毒性心肌炎的关系 ,并为寻找治疗该病的新方法提供理论依据。方法 通过聚合酶链反应技术选择柯萨奇B病毒性心肌炎患儿 31例作为病例组 ,选择相同例数的同龄健康儿童作为对照组。以酶联免疫吸附试验 (ELISA)法检测实验对象血清中IL 6 ,SIL 6Rα,SIL 6Rβ 水平的变化。所测得的实验数据经统计学处理 ,行 q检验和相关分析。结果 病毒性心肌炎急性期患儿血清中IL 6、SIL 6Rα、SIL 6Rβ 浓度均升高 (P <0 .0 1 ) ;病毒性心肌炎恢复期患儿血清中IL 6、SIL 6Rα、SIL 6Rβ 的水平与正常对照组相比差异无显著性 (P >0 .0 5 ) ;病毒性心肌炎急性期患儿血清中IL 6与SIL 6Rα 浓度变化呈正相关 (r =0 .771 ,P <0 .0 1 ) ,SIL 6Rβ 与IL 6、SIL 6Rα 浓度变化均无相关关系。结论 病毒性心肌炎急性期血清中IL 6水平升高 ,在病毒性心肌炎中发挥炎症防御性作用 ;SIL 6Rα 水平升高 ,且与IL 6水平变化呈正相关 ,是IL 6的激动剂 ,通过扩大IL 6的生物学作用 ,减少心肌细胞的损害。故血清中IL 6、SIL 6Rα 浓度变化可作为VM患者免疫能力监测的指标 ,并预示IL 6、SIL 6Rα 重组分子和激动剂的研制及应用  相似文献   

13.
There is growing evidence that sepsis-related complications in neonates are crucially mediated by the action of proinflammatory cytokines. It has previously been demonstrated that elevated IL-6 and IL-8 levels can predict brain damage and chronic lung disease in preterm infants. However, it is the current view that neonates have a reduced capability to produce proinflammatory cytokines. To clarify this issue, we analyzed the inflammatory response in term and preterm infants directly at the single cell level by flow cytometry. Endotoxin challenge was performed under defined conditions on monocytes obtained from 50 healthy adults and 119 neonates, which consist of 45 term infants, 63 preterm infants (26.1-36.7 wk of gestational age), and 11 preterm infants with proven infection (24.6-29.9 wk). Our results challenge the existing view of an immature inflammatory response by demonstrating that term infants and preterm infants display a higher percentage of IL-6- and IL-8-positive cells than adults. After preincubation with dexamethasone the number of cytokine-positive cells decreased in all groups, but the number of IL-8-positive cells remained higher in term and preterm infants >32 wk compared with adults. These observations demonstrate not only a well-developed but also an enhanced inflammatory response in term and preterm infants. Under consideration of several detrimental effects of IL-6 and IL-8, our data may have major implications on the pathophysiology of inflammatory-triggered neonatal diseases.  相似文献   

14.
15.
16.
哮喘患儿血白细胞介素-2、10、13检测的临床意义   总被引:7,自引:1,他引:7  
目的 探讨哮喘患儿外周血白细胞介素 2 (IL 2 )、IL 10、IL 13的变化及其在哮喘发病机制中的作用。方法 用ELISA双抗体夹心法测定 16例哮喘患儿及 10例正常儿童血浆IL 2、IL 10、IL 13的含量。结果 哮喘组血浆IL 2、IL 13水平均明显高于正常对照组 ,IL 10水平明显低于正常对照组 (P均 <0 .0 5)。结论 IL 2、IL 10、IL 13等细胞因子参与儿童哮喘发病的病理生理过程 ,可作为病情变化的监测指标  相似文献   

17.
Interleukin (IL)-1 and IL-2 may participate in the systemic inflammatory response and hypergammaglobulinaemia observed in patients with cystic fibrosis. Thirty seven patients with cystic fibrosis were compared with 25 normal controls. High IgG and IgM concentrations were associated with more severe pulmonary disease. IL-1 alpha and soluble IL-2 receptor concentrations were higher in the cystic fibrosis group than in the controls and also correlated with concentrations of IgG and IgM. These results suggest that these cytokines may contribute to enhanced immunoglobulin synthesis and silent inflammatory activity in clinically stable patients with cystic fibrosis.  相似文献   

18.
In a prospective study, plasma interleukin-6 (IL-6) and interleukin-10 (IL-10) levels were measured by enzyme-linked immunosorbent assay in 45 premature neonates (25–34 weeks gestational age) with signs and symptoms of suspected sepsis at 0, 12 and 24 h; C-reactive protein (CRP) was measured at 0–24 h after enrolment. Six subjects were excluded due to insufficient blood sampling. The remaining 39 neonates were assigned to one of three groups: 25 newborns with sepsis (blood culture positive), seven with pneumonia (positive results on broncho-alveolar lavage fluid culture and characteristic chest radiography) and seven with necrotising enterocolitis (NEC) (characteristic intestinal and radiological signs according to the criteria of Bell et al.). A group of 20 healthy preterm neonates represented control subjects. On admission, higher levels of IL-6, IL-10 and CRP were observed in neonates with sepsis: IL-6 (median 1500 pg/ml, range 487–10000 pg/ml), IL-10 (median 113 pg/ml, range 70–196 pg/ml), CRP (median 22 mg/l, range 4–80 mg/l); pneumonia: IL-6 (median 1500 pg/ml, range 747–8000 pg/ml, IL-10 (median 84 pg/ml, range 76–92 pg/ml), CRP (median 10 mg/l, range 8–33 mg/l) and NEC: IL-6 (median 6650 pg/ml, range 1595–7950 pg/ml), IL-10 (median 80 pg/ml, range 61–147 pg/ml), CRP (median 3 mg/l, range 2.8–8 mg/l) as compared to controls (IL-6 median 208 pg/ml, range 198–349 pg/ml; IL-10 median 36 pg/ml, range 19–50 pg/ml; CRP median <2 mg/l) (P < 0.05). In neonates with sepsis, IL-6 levels were significantly correlated with IL-10 levels (r=0.65; P=0.04) at the time of the second sample. The highest IL-6 levels were observed at onset, while IL-10 was predominant 12 h later. On admission, IL-10 and CRP levels were significantly higher in non-survivors (IL-10 median 507 pg/ml, range 422–753 pg/ml; CRP median 123 mg/l, range 20–219 mg/l) than in survivors (IL-10 median 76 pg/ml, range 61–143 pg/ml; CRP median 8 mg/l range 3–46 mg/l), while IL-10 levels were significantly higher (P < 0.05) also 12 h after admission (non-survivors: IL-10 median 600 pg/ml, range 538–800 pg/ml; survivors: IL-10 median 74 pg/ml, range 53–161 pg/ml). IL-6 and IL-10 levels were significantly correlated with CRP levels on admission (r=0.45; P=0.05). Conclusion Preterm neonates with sepsis, pneumonia or necrotising enterocolitis showed increased interleukin-6, interleukin-10 and C-reactive protein levels. High interleukin-10 concentration was associated with mortality and could be an early indicator of prognosis. Received: 21 November 2000 / Accepted: 23 January 2001  相似文献   

19.
Interleukin (IL)-1 and IL-2 may participate in the systemic inflammatory response and hypergammaglobulinaemia observed in patients with cystic fibrosis. Thirty seven patients with cystic fibrosis were compared with 25 normal controls. High IgG and IgM concentrations were associated with more severe pulmonary disease. IL-1 alpha and soluble IL-2 receptor concentrations were higher in the cystic fibrosis group than in the controls and also correlated with concentrations of IgG and IgM. These results suggest that these cytokines may contribute to enhanced immunoglobulin synthesis and silent inflammatory activity in clinically stable patients with cystic fibrosis.  相似文献   

20.
OBJECTIVE: To study plasma levels of IL-1beta and IL-6 in order to distinguish the presence of bacterial infection in newborn infants with fever. METHODS: A cohort of 117 newborn infants with postnatal age equal to or less than 5 days, with no previous use of antibiotic therapy, and with clinical suspicion of bacterial infection was studied from July 1995 through August 1996. Those with definite criteria for sepsis were considered infected. Fever was defined as axillar temperature > 37.5 degrees C in three independent measurements. The patients were classified in four different groups: Group 1: infected with fever; Group 2: infected without fever; Group 3: not infected with fever; Group 4: not infected without fever. Complete blood count, platelet count, blood or other fluid cultures, and plasmatic levels of IL-1beta and IL-6 were collected before the beginning of antibiotic therapy. RESULTS: Of the 117 newborn infants studied were 66 infected and 51 not infected. Fever was present in 45 (38.46%). The median values of IL-1beta and IL-6 were significantly higher in newborn infants with fever than in those with no fever. There were significant differences between groups 1 and 2, 1 and 4, and 2 and 3 for IL-1beta. There were no significant differences between groups 2 and 4, and 1 and 3 for IL-1beta. Eight (72%) newborn infants with no infection and no fever had environment heating, and 3 had dehydration. There were no differences in median IL-6 levels between groups 1 and 2, and 3 and 4. There were significant differences in the median IL-6 levels between groups 1 and 3, and 1 and 4. CONCLUSIONS: IL- 6 is a marker of early neonatal sepsis. IL-1beta is related to neonatal fever response independently of the presence of bacterial infection.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号